Dian Pinto, a 47-year-old resident of Mukamar parish, is currently undergoing treatment at A J Hospital & Research Centre, ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca announced that it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, a figure significantly lower than some investors had feared. The ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...